For the Inventor, By the Inventor

Enter assignee name

Zeist, Netherlands

Pantarhei Bioscience B.v.

USPTO Granted Patents = 20

% Expired Patents = 15.0

CIPO Patents = 16

EPO Patents = 9

Forward Citations = 454

Loading Chart...

Loading Chart...

9 inventors (with patents filed for the assignee):

Herman Jan Tijmen Coelingh Bennink (20 out of 32 patents)

Evert Johannes Bunschoten (11 out of 14 patents)

Christian Franz Holinka (8 out of 8 patents)

4. Monique Visser (4 out of 4 patents)

5. Johannes Jan Platteeuw (1 out of 19 patents)

6. Martinus Antonius Hermanus Maria Wiegerinck (1 out of 1 patent)

7. Petrus Johannes Boerrigter (1 out of 1 patent)

8. René Frank Van Der Linden (1 out of 1 patent)

9. Nafis Ahmed Rahman (1 out of 1 patent)

10. Mark Theodoor Verhaar (1 patent)

11. Erwin Gerardus Jacobus Warmerdam (1 patent)

12. Herman Jan Coelingh Bennink (0 patent)

13. Thomas Koch (0 patent)

14. Erwin Gerardus Warmerdam (0 patent)

15. Herjan Jan Tijmen Coelingh Bennink (0 patent)

20 patents: Sort by Forward Citations

1. 11819542 - Immunotherapeutic method for treating lung cancer by administering a polypeptide comprising an epitope of hZP3 (2023-11-21),

2. 10179107 - Tablet containing dehydroepiandrosterone (DHEA) (2019-01-15),

3. 9295720 - Immunotherapeutic method for treating prostate cancer (2016-03-29),

4. 9040509 - Method of treating human skin and a skin care composition for use in such a method (2015-05-26),

5. 9034854 - Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy (2015-05-19),

6. 8987240 - Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy (2015-03-24),

7. 8801627 - Sampler (2014-08-12),

8. 8518923 - Treatment or prevention of hypertensive disorders of pregnancy or fetal growth retardation (2013-08-27),

9. 8367647 - Treatment of meconium aspiration syndrome with estrogens (2013-02-05),

10. 8236785 - Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method (2012-08-07),

11. 8071576 - Method of preventing or treating benign gynaecological disorders (2011-12-06),

12. 8048869 - Pharmaceutical composition for use in hormone replacement therapy (2011-11-01),

13. 8026228 - Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy (2011-09-27),

14. 7968514 - Pharmaceutical composition for treating or preventing ovarian cancer (2011-06-28),

15. 7943604 - Method of treating human skin and a skin care composition for use in such a method (2011-05-17),

Company Overview

Pantarhei Bioscience B.V. is a biopharmaceutical company based in Zeist, Netherlands, specializing in the development of innovative therapies for unmet medical needs. The organization focuses on drug discovery and development, particularly in the fields of women's health and endocrinology. By leveraging advanced scientific research and technology, Pantarhei aims to create effective treatments that enhance patient outcomes and improve quality of life. Their commitment to innovation positions them as a key player in the biopharmaceutical landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

20 Patents

#1 in Zeist

#362 in Netherlands

#31,295 in the World

Zeist, Netherlands

Pantarhei Bioscience B.v.

Forward Citations = 454

9 inventors:

Herman Jan Tijmen Coelingh Bennink (20 out of 32 patents)

Evert Johannes Bunschoten (11 out of 14 patents)

Christian Franz Holinka (8 out of 8 patents)

4. Monique Visser (4 out of 4 patents)

5. Johannes Jan Platteeuw (1 out of 19 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Pantarhei Bioscience B.v.. Retrieved from https://idiyas.com/company/pantarhei-bioscience-b-v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…